Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Timing of Myelosuppression During Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring Recommendations
Clinical Gastroenterology and Hepatology , 11/04/09
Lewis JD et al. – The high incidence of severe myelosuppression justifies frequent monitoring during the first 8 weeks of therapy. Subsequently, the rate of severe myelosuppression and the proportion of patients who progress from mild to severe myelosuppression decrease, justifying less–frequent monitoring.
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09
Methotrexate for maintenance of remission in Crohn's disease
Cochrane Reviews, 10/27/09
Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
Journal of Viral Hepatitis, 11/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


